Cargando…
Targeting Angiogenesis in Prostate Cancer
Prostate cancer is the most commonly diagnosed cancer among men in the Western world. Although localized disease can be effectively treated with established surgical and radiopharmaceutical treatments options, the prognosis of castration-resistant advanced prostate cancer is still disappointing. The...
Autores principales: | Melegh, Zsombor, Oltean, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600172/ https://www.ncbi.nlm.nih.gov/pubmed/31151317 http://dx.doi.org/10.3390/ijms20112676 |
Ejemplares similares
-
Alternative Splicing in Angiogenesis
por: Bowler, Elizabeth, et al.
Publicado: (2019) -
The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis
por: Kollareddy, Madhu, et al.
Publicado: (2017) -
Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion
por: Bullock, Nicholas, et al.
Publicado: (2016) -
Angiogenesis inhibitors in the treatment of prostate cancer
por: Hwang, Clara, et al.
Publicado: (2010) -
Angiogenesis Inhibition in Prostate Cancer: An Update
por: Sarkar, Chandrani, et al.
Publicado: (2020)